In the Antiphospholipid Antibodies and Stroke Study (APASS), a prospective observational study, including 720 positive aPL patients with previous stroke event, warfarin with a target INR 1.4–2.8 was not proven to be superior to aspirin (325 mg/day) in stroke prevention over two years. Here, FASLG is linked to stroke disorder.